GIPR and Parkinson disease: In a mouse model of PD, a novel GLP-1R/GIPR dual agonist outperformed single GLP-1R agonist NLY01 in reducing the levels of activated NF-κB, TNF-α, IL-6, and IL-1β, as well as mitigating microglial activation and reactive astrogliosis [93].